Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RG2133 (2',3',5'-tri-O-acetyluridine) | Drug |
Mitochondrial Disease
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D028361 | Mitochondrial Diseases |
| ID | Term |
|---|---|
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000609666 | uridine triacetate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided